USOR 23066 - STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma

TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Disease Types: Cholangiocarcinoma, STAR: Selected Trials Available for Accelerated Four Week Rollout

Available at: Arlington Heights, Niles, Chicago Resurrection